Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable

Amarin Corporation reported a significant Q2 2025 revenue beat, reaching $72.7 million against a $42.55 million forecast, and a much narrower loss per share of -$0.03 versus -$1 expected. This strong performance was primarily driven by robust growth in European and other international markets, with European revenue nearly doubling year-over-year, which largely offset a 17% decline in U.S. revenue due to generic competition. The company is strategically focusing on global expansion through partnerships, implementing a restructuring for $70 million in operating expense savings, and aims for positive cash flow, supported by a strong balance sheet with $298.7 million in cash.

Analysis

Amarin Corporation's Q2 2025 results reveal a significant strategic pivot, characterized by strong execution in international markets and a managed decline in the U.S. The company reported a substantial top-and-bottom-line beat, with revenue of $72.7 million exceeding forecasts by over 70% and an EPS loss of just $0.03, far better than the expected $1.00 loss. This performance was driven by a near doubling of European product revenue year-over-year and a 31% increase in licensing revenue, largely from an upfront payment via its new partnership with Recordati. This growth successfully offset the 17% decline in U.S. product revenue, which continues to face pricing pressure from generic competition. The strategic shift is clear: Amarin is de-emphasizing its direct U.S. commercial footprint in favor of a lean, royalty-focused model centered on ex-U.S. growth. This is reinforced by a major restructuring initiative expected to deliver $70 million in operating expense savings over the next twelve months. The company's financial position remains robust, with a cash balance of $298.7 million and minimal debt, providing a solid foundation to execute this transition and pursue further strategic opportunities with its advisor, Barclays.

Key Decisions for Investors

• Investors should re-evaluate Amarin as a strategic turnaround story, where the primary value driver has shifted from U.S. product sales to the execution of its international partnership model and the realization of significant cost savings.
• Monitor quarterly reports for commentary on European end-market demand under the new Recordati partnership, as this is the most critical metric for validating the new growth thesis and the company's path to positive cash flow.
• Factor in the continued, albeit managed, erosion of the U.S. business due to generic competition, but note management's strategy to maintain market share and defer the launch of an authorized generic.
• The ongoing strategic review with Barclays introduces a potential M&A catalyst, which could unlock value beyond the operational turnaround and should be considered a key variable in the investment case.